Elan And Biogen Idec Initiate First Clinical Trial Of TYSABRI(R) In Oncology - First Multiple Myeloma Patient Treated

 06.09.2008 08:12   medicalnewstoday.com

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced the initiation of the first clinical trial of TYSABRI® (natalizumab) in oncology. The first dose of TYSABRI was administered yesterday in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of TYSABRI in patients with relapsed or refractory multiple myeloma.

World Cancer